Ribon Therapeutics

Ribon Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing first-in-class small molecule inhibitors to block the essential ability of cancer cells to survive under stress.Ribon Therapeutics combines a proprietary platform with drug discovery expertise to build a broad pipeline based on small molecule inhibitors targeting a novel family of enzymes, with our initial focus being on monoPARP. MonoPARP plays a critical role in regulating stress responses that enable cancer cell survival, and emerging science links monoPARP activity to disease progression. There are 12 different monoPARPs involved in various stress responses, offering significant therapeutic potential for monoPARP inhibitors across a wide range of therapeutic areas. In oncology, these targets provide new treatment opportunities for a broad array of tumor types, both as single agents and in combination therapies.